WALTHAM, Mass., June 04, 2020 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company pioneering targeted C3 therapies, […]
Collects Industry-Leading April Rental Collections of 83.6%May Rental Collection of 67.4%, Higher than Reported Industry Average of 59.5%(1)HOUSTON, June 04, […]
– IBIO-201, a subunit vaccine combining SARS-CoV-2 spike protein antigens with the Company’s proprietary LicKM booster technology, advances to preclinical […]